A potential criticism of our line of thinking could be that there is no haploinsufficient effect of a BRCA1 or BRCA2 mutation, and that anti-oestrogen treatment functions only as a secondary preventer of breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.